A Phase 2 interventional study of NP-101 and Placebo in COVID-19, sponsored by Novatek Pharmaceuticals. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Novatek Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 518th largest by enrollment of the 1,321 interventional ones that give a count, is one of 131 that started in 2023, is one of 349 in phase 2, and was the 1,620th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 131 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 170 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
Novatek Pharmaceuticals is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Novatek Pharmaceuticals has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of NP-101 in treating high-risk participants who have tested positive for Covid-19. The main question[s] it aims to answer are:
Participants will [describe the main tasks participants will be asked to do, treatments they'll be given and use bullets if it is more than 2 items]. If there is a comparison group: Researchers will compare [insert groups] to see if [insert effects].
This is a Phase IIa/IIb multicenter, interventional, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of NP-101 in outpatient high-risk COVID-19 positive participants. Blinding roles: Participants, Investigators and Sponsor
The study is comprised of two parts (Phase IIa and Phase IIb) and four cohorts. The first part of the trial (IIa) involves three cohorts and is a dose escalation study designed to select the maximum tolerated dose for use in the second part (IIb) of the study. In the dose escalation (Phase IIa) portion of the trial (n= 60), qualified participants will be enrolled in a parallel dose escalation design and randomized in a 3:1 [active+best supportive care (BSC):placebo+BSC]ratio to one of three cohorts of 20 participants each (15 active +BSC, 5 placebo + BSC). Cohort 1 (15 participants taking 600 mg capsules for a total daily dose of 3 grams of NP-101 plus BSC and 5 participants taking placebo plus BSC), and Cohort 2 (15 participants taking 600 mg capsules for a total daily dose of 4.8 g of NP-101+ BSC and 5 participants taking placebo plus BSC will run concurrently since acceptable safety data for the 3 g dose was obtained in an earlier phase II study.
Cohort 1 will receive either 3 g Total Daily Dose (TDD) of NP-101 + BSC or Placebo+ BSC, Cohort 2 will receive either 4.8 g TDD of NP-101 +BSC or placebo + BSC) and Cohort 3 (15 participants taking 600 mg capsules for a total daily dose of 6 g of NP-101 + BSC and 5 participants taking placebo plus BSC.) Safety will be evaluated according to the terms of the Statistical Analysis Plan (SAP). In the second portion of the trial (Phase IIb), Participants enrolled in Cohort 4 (n= 248) will be randomized in a ratio of 1:1 (active+BSC : placebo+BSC) and will receive the Maximum Tolerated Daily Dose (MTDD) as determined by the parameters set by the SAP and approved by the pharmacovigilance team.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be considered high risk, participants should have at least one of the following conditions:
Exclusion Criteria:
Significant hepatic disease (/AST> 4 times the ); any laboratory parameter >/= 4 times the ULN or count \<100,000/µ L or neutrophilic granulocyte absolute count
o \<500/mm3
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase IIa - Dose escalation. 3g cohort and 4.8g cohort run simultaneously, followed by a 6 g cohort. Administered in 600 g capsules of NP-101 for a total daily dose of 3g, 4.8g and 6g adminstered BID. Administered for 14 days.Establish MTDD Phase IIB - Continue study with MTDD as established above.
Drug: NP-101
As above, except dosed with matching placebo capsules.
Other: Placebo
Drug pages: Nigella sativa oil · Black Seed Oil Extract Supplement
NP-101 is an organically derived, GMP manufactured product covered under IND #152687.
Also known as: TQ Formula
Identical placebo
Establishment of MTDD
Number of DLTS (Dose Limiting Toxicities) in the NP-101 arm at each dose compared to placebo and the safety threshold. This outcome measure ONLY APPLIES TO the Phase-IIa (Dose-finding) component of the trial.
Time frame: Fourteen days per dose (Phase IIA Only)
Safety and Tolerability of NP-101 vs Placebo (Phase IIa and IIb)
Evaluation of the number of overall adverse events, related adverse reactions, adverse events leading to discontinuation of study drug, hospitalization, or death.
Time frame: Through Day 45
Time to Sustained Clinical Recovery
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. This outcome measure is defined as the difference of Sustained Clinical Recovery (SCR) rates on Day 5 in patients taking the MTDD of NP-101 vs Placebo.
Time frame: Through Day 5
Difference of Change in Log2 of Viral Load From Baseline to Day-7 Between NP-101 and Placebo
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7.
Time frame: Enrollment to Day-7 on study
Difference of Change in ORF1 Gene From Baseline to Day-7 Between NP-101 and Placebo
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7
Time frame: Enrollment to Day-7
Difference in Change of E-Gene From Baseline to Day-7 Between N101 and Placebo
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7.
Time frame: From Enrollment to Day-7
Differenc in Change of N-Gene From Baseline to Day-7 Between NP-101 and Placebo
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. . With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7.
Time frame: From enrollment to Day-7
RT-PCR Negative/Undetectable Rate at Day 7
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the percentage of RT-PCR negative/undetectable (i.e., viral clearance) on Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo
Time frame: Days 0 to 7
RT-PCR Negative/Undetectable on Day-14
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the percentage of RT-PCR negative/undetectable (i.e., viral clearance) on Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo
Time frame: Day 0 to Day-14
Median Time to Sustained Clinical Recovery
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this aim, we compare the median days from randomization to the attainment of Sustained Clinical Recovery between NP-101 and Placebo arms
Time frame: From Day-0 to Day-28
Median Day to Complete Clinical Recovery
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this aim, we compare the median days from randomization to the attainment of Sustained Clinical Recovery between NP-101 and Placebo arms
Time frame: From Day-0 to Day-28
Median Days to Complete Clinical Resolution
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this aim, we compare the median days from randomization to the attainment of the complete clinical resolution between NP-101 and Placebo.
Time frame: From Day-0 to Day-28
Difference of the Change From Randomization to Day-7 of Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+ Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. Markers are absolute counts of cells per cubic milimeter.
Time frame: From Day-0 to Day-7
Difference of the Change From Randomization to Day-7 ın the Ratio of the Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in the ratio of CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. Both CD4+ and CD8+ are measured as absolute counts of cells per cubic milimeter.
Time frame: From Day-0 to Day-7
Difference of the Change From Randomization to Day-7 of Percentages of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+ Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. These marker entries represent the percentages of the combination of these immune cell types or their percentages in the biological sample.
Time frame: From Day-0 to Day-7 Cell Percentages
Difference of the Change From Randomization to Day-14 of Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+. Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. Markers are absolute count of cells per cubic milimeter.
Time frame: From Day*0 to Day-14
Difference of the Change From Randomization to Day-14 ın the Ratio of the Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in the ratio of CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. Both CD4+ and CD8+ are measured as absolute counts of cells per cubic milimeter.
Time frame: From Day-0 to Day-14
Difference of the Change From Randomization to Day-14 of Percentages of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms.
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+. Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. These Markers represent the percentages of the combination of these immune cell types or their percentages in the biological sample.
Time frame: From Day-0 to Day-14
Proportion of Participants With Symptom Progression
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the rate of disease progression measured by the worsening by the Covid-19 symptoms from 'none' or 'mild' to 'moderate' or 'severe' and remaining at that level for at least two days before alleviation or resolution, or the experience of hospitalization or death due to Covid-19 symptom worsening in participants taking the MED of NP-101 versus placebo
Time frame: From Day-0 to Day28
Proportion of Paticipants With Long-Covid Symptoms
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the rate of Long- Covid symptoms in participants taking the MED of NP-101 versus placebo. A patient will be classified as having experienced symptoms indicative of Long- Covid if they reported any new or ongoing mild, moderate, or severe Long- Covid symptoms captured on the daily symptom questionnaire, on any of the following days: Day 30 ± 2 days, Day 37 ± 2 days, or Day 45 ± 2 days
Time frame: Day-29 to Day-45
60 participants were enrolled during the Phase-IIa component of the trial during which we identified the Phase-IIb dose. The remaining 110 participants were enrolled on the study during the Phase-IIb component.
| Milestone | Phase-IIa NP-101, Dose 3g | Phase-IIa Placebo, Dose 3g | Phase-IIa NP-101, Dose 4.8g | Phase-IIa Placebo, Dose 4.8g | Phase-IIa NP-101, Dose 6g | Phase-IIa Placebo, Dose 6g | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|---|---|---|---|---|---|
| Started | 15 | 5 | 15 | 5 | 15 | 5 | 50 | 60 |
| Completed | 15 | 5 | 15 | 5 | 15 | 5 | 50 | 60 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of DLTS (Dose Limiting Toxicities) in the NP-101 arm at each dose compared to placebo and the safety threshold. This outcome measure ONLY APPLIES TO the Phase-IIa (Dose-finding) component of the trial.
| Participants | Phase-IIa NP-101, Dose 3g | Phase-IIa NP-101, Dose 4.8g | Phase-IIa NP-101, Dose 6g |
|---|---|---|---|
| Establishment of MTDD | 0 | 0 | 0 |
Evaluation of the number of overall adverse events, related adverse reactions, adverse events leading to discontinuation of study drug, hospitalization, or death.
| Participants | Phase-IIa NP-101, Dose 3g | Phase-IIa Placebo, Dose 3g | Phase-IIa NP-101, Dose 4.8 | Phase-IIa Placebo, Dose 4.8g | Phase-IIa NP-101, Dose 6g | Phase-IIa Placebo, Dose 6g | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|---|---|---|---|---|---|
| Number of Participants with Adverse Events (AE) attributable to the study madication | 1 | 1 | 4 | 2 | 7 | 2 | 8 | 12 |
| Number of Participants with Adverse Events (AE) regardless of attribution | 4 | 3 | 6 | 3 | 12 | 4 | 19 | 32 |
| Number of Patients with serious adverse events (SAE) attributable to the study medication | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Patients with serious adverse events (SAE) regardless of attributable to the study medication | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Number of Patients with adverse events (AE) leading to d/c of study drug, hospitalization or death. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. This outcome measure is defined as the difference of Sustained Clinical Recovery (SCR) rates on Day 5 in patients taking the MTDD of NP-101 vs Placebo.
| Participants | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| Time to Sustained Clinical Recovery | 28 | 36 |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7.
| Log-2 of the number of copies/mL | Phase-IIb nP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| Difference of Change in Log2 of Viral Load From Baseline to Day-7 Between NP-101 and Placebo | 5.11 ± 7.09 | 9.63 ± 4.43 |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7
| No of amplification cycles for detection | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| Difference of Change in ORF1 Gene From Baseline to Day-7 Between NP-101 and Placebo | 5.35 ± 7.34 | 10.08 ± 4.64 |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7.
| No of amplification cycles for detection | Phase IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| Difference in Change of E-Gene From Baseline to Day-7 Between N101 and Placebo | 4.92 ± 7.76 | 10.14 ± 5.01 |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. . With this outcome measure, we aim to compare the change in viral load and cycle threshold profiles from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. As Viral Load and Cycle Threshold values were not available on Day-14 as the RT-PCR assessment of Covid-19 was negative, we are able to provide the change only from Baseline to Day-7.
| No of amplification cycles for detection | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| Differenc in Change of N-Gene From Baseline to Day-7 Between NP-101 and Placebo | 5.78 ± 7.26 | 9.79 ± 4.00 |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the percentage of RT-PCR negative/undetectable (i.e., viral clearance) on Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo
| Participants | Phase IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| RT-PCR Negative/Undetectable Rate at Day 7 | 36 | 46 |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the percentage of RT-PCR negative/undetectable (i.e., viral clearance) on Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo
| Participants | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| RT-PCR Negative/Undetectable on Day-14 | 47 | 54 |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this aim, we compare the median days from randomization to the attainment of Sustained Clinical Recovery between NP-101 and Placebo arms
| Days from enrollment | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| Median Time to Sustained Clinical Recovery | 5 (4 to 5) | 4 (4 to 5) |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this aim, we compare the median days from randomization to the attainment of Sustained Clinical Recovery between NP-101 and Placebo arms
| Days from Enrollment | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| Median Day to Complete Clinical Recovery | 18 (7 to 23) | 20.5 (12 to 25) |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this aim, we compare the median days from randomization to the attainment of the complete clinical resolution between NP-101 and Placebo.
| Days from Enrollment | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| Median Days to Complete Clinical Resolution | 19 (11 to 27) | 23.5 (16 to 27) |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+ Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. Markers are absolute counts of cells per cubic milimeter.
| Counts of cells/mm^3 | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| CD45+ CCR7 CD8⁺ (Absolute Count as cells/mm^3) | 648.10 ± 362.76 | 553.27 ± 317.40 |
| CD45⁺ CCR7⁺ CD8⁺ (Absolute Count as cells/mm^3) | 647.75 ± 411.72 | 750.81 ± 505.66 |
| CXCR3⁺ CD4⁺ (Absolute Count as cells/mm^3) | 125.86 ± 153.98 | 130.01 ± 141.1 |
| CCR7⁺ CXCR3⁺ CD8⁺ (Absolute Count as cells/mm^3) | 16.80 ± 26.67 | 14.17 ± 15.66 |
| CXCR3⁺ CD8⁺ (Absolute Count as cells/mm^3) | 1573.88 ± 609.67 | 1496.86 ± 518.6 |
| CD8⁺ CD4⁺ (Absolute Count as cells/mm^3) | 21.96 ± 32.77 | 19.05 ± 17.12 |
| CCR7⁺ CXCR3⁺ CD4⁺ (Absolute Count as cells/mm^3) | 109.06 ± 130.88 | 110.59 ± 124.01 |
| CD45⁺ CD3⁺ CD8⁺ (Absolute Count as cells/mm^3) | 544.13 ± 235.08 | 530.17 ± 240.16 |
| CD45⁺ CD3⁺ CD4⁺ (Absolute Count as cells/mm^3) | 1051.97 ± 398.08 | 1018.03 ± 381.23 |
| CD45_LYMPHOGATE (Absolute Count as cells/mm^3) | 2256.04 ± 738.12 | 2198.00 ± 655.61 |
| CD45 CCR7⁺ CD8⁺ (Absolute Count as cells/mm^3) | 181.45 ± 146.63 | 175.87 ± 179.88 |
| CD45⁺ CCR7⁺ CD4⁺ (Absolute Count as cells/mm^3) | 942.70 ± 400.62 | 954.23 ± 479.38 |
| CD45 CCR7 CD4⁺ (Absolute Count as cells/mm^3) | 297.09 ± 238.68 | 286.70 ± 202.4 |
| CD45⁺ CCR7 CD8⁺ (Absolute Count as cells/mm^3) | 778.96 ± 457.08 | 737.71 ± 401.83 |
| CD45⁺ CD3⁺ CD16⁺ (Absolute Count as cells/mm^3) | 260.96 ± 142.8 | 262.09 ± 135.68 |
| CD45 CCR7⁺ CD4⁺ (Absolute Count as cells/mm^3) | 945.41 ± 464.32 | 903.43 ± 411.39 |
| CD45⁺ CD3⁺ CD19⁺ (Absolute Count as cells/mm^3) | 323.79 ± 143.12 | 314.21 ± 134.1 |
| CD45⁺ CD3⁺ (Absolute Count as cells/mm^3) | 1640.57 ± 577.19 | 1592.98 ± 512.35 |
| CD45 CCR7 CD8⁺ (Absolute Count as cells/mm^3) | 34.64 ± 17.68 | 33.94 ± 15.95 |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in the ratio of CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. Both CD4+ and CD8+ are measured as absolute counts of cells per cubic milimeter.
| Ratio | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| Difference of the Change From Randomization to Day-7 ın the Ratio of the Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms. | 2.11 ± 0.83 | 2.17 ± 1.19 |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+ Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. These marker entries represent the percentages of the combination of these immune cell types or their percentages in the biological sample.
| Percentage (%) | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| CXCR3⁺ CD8⁺ (%) | 0.58 ± 9.74 | -1.21 ± 8.31 |
| CD45 CCR7 CD8⁺ (%) | 0.99 ± 8.62 | -0.29 ± 9.77 |
| CXCR3⁺ CD4⁺ (%) | -0.35 ± 9.95 | -0.27 ± 7.59 |
| CCR7⁺ CXCR3⁺ CD8⁺ (%) | -0.29 ± 6.83 | 0.04 ± 6.30 |
| CD45 CCR7⁺ CD8⁺ (%) | -0.50 ± 10.43 | -1.99 ± 7.50 |
| CCR7⁺ CXCR3⁺ CD4⁺ (%) | -0.06 ± 1.36 | -0.32 ± 1.81 |
| CD8⁺ CD4⁺ (%) | 0.01 ± 0.88 | -0.08 ± 0.45 |
| CD45⁺ CD16⁺ (%) | -0.94 ± 4.67 | -1.43 ± 6.19 |
| CD45⁺ CD3⁺ CD4⁺(%) | 0.04 ± 4.11 | 0.06 ± 3.76 |
| CD45 CCR7⁺ CD4⁺ (%) | -0.49 ± 9.27 | 0.34 ± 11.30 |
| CD45⁺ CD3⁺ CD8⁺ (%) | -0.05 ± 3.18 | 1.04 ± 6.47 |
| CD45⁺ CCR7 CD8⁺ (%) | 0.02 ± 5.33 | 1.95 ± 3.59 |
| CD45⁺ CD3⁺ (%) | 0.22 ± 4.82 | -0.52 ± 6.34 |
| CD45⁺ CD3⁺ CD19⁺ (%) | 0.62 ± 2.67 | 1.83 ± 3.03 |
| CD45⁺ CCR7⁺ CD4⁺ (%) | -0.49 ± 9.27 | 0.34 ± 11.30 |
| CD45 CCR7 CD4⁺ (%) | 0.26 ± 8.61 | 2.10 ± 8.24 |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+. Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. Markers are absolute count of cells per cubic milimeter.
| cells/mm^3 | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| CD45+ CCR7 CD8⁺ (Absolute Count as cells/mm^3) | 630.96 ± 348.84 | 568.31 ± 329.50 |
| CD45⁺ CCR7⁺ CD8⁺ (Absolute Count as cells/mm^3) | 627.99 ± 401.92 | 678.60 ± 448.71 |
| CCR7⁺ CXCR3⁺ CD8⁺ (Absolute Count as cells/mm^3) | 16.61 ± 29.77 | 14.84 ± 18.14 |
| CXCR3⁺ CD8⁺ (Absolute Count as cells/mm^3) | 1560.93 ± 521.79 | 1485.02 ± 506.68 |
| CD8⁺ CD4⁺ (Absolute Count as cells/mm^3) | 18.82 ± 16.67 | 20.10 ± 17.94 |
| CCR7⁺ CXCR3⁺ CD4⁺ (Absolute Count as cells/mm^3) | 103.07 ± 123.04 | 106.19 ± 89.02 |
| CD45⁺ CD3⁺ CD8⁺ (Absolute Count as cells/mm^3) | 524.73 ± 215.27 | 496.46 ± 219.66 |
| CD45⁺ CD3⁺ CD4⁺ (Absolute Count as cells/mm^3) | 1018.27 ± 396.09 | 963.24 ± 403.13 |
| CD45_LYMPHOGATE (Absolute Count as cells/mm^3) | 2219.08 ± 687.91 | 2075.25 ± 665.69 |
| CD45 CCR7⁺ CD8⁺ (Absolute Count as cells/mm^3) | 168.47 ± 125.91 | 146.68 ± 107.73 |
| CD45⁺ CCR7⁺ CD4⁺ (Absolute Count as cells/mm^3) | 924.25 ± 345.16 | 912.86 ± 445.05 |
| CD45 CCR7 CD4⁺ (Absolute Count as cells/mm^3) | 278.61 ± 168.56 | 266.41 ± 181.75 |
| CD45⁺ CCR7 CD8⁺ (Absolute Count as cells/mm^3) | 775.97 ± 401.74 | 672.74 ± 362.52 |
| CD45⁺ CD3⁺ CD16⁺ (Absolute Count as cells/mm^3) | 662.39 ± 2851.03 | 252.65 ± 137.30 |
| CD45 CCR7⁺ CD4⁺ (Absolute Count as cells/mm^3) | 937.05 ± 440.55 | 841.36 ± 426.28 |
| CD45⁺ CD3⁺ CD19⁺ (Absolute Count as cells/mm^3) | 325.93 ± 135.74 | 288.91 ± 125.42 |
| CD45⁺ CD3⁺ (Absolute Count as cells/mm^3) | 1587.71 ± 561.10 | 1501.06 ± 522.98 |
| CD45 CCR7 CD8⁺ (Absolute Count as cells/mm^3) | 35.26 ± 16.31 | 32.75 ± 15.22 |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in the ratio of CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. Both CD4+ and CD8+ are measured as absolute counts of cells per cubic milimeter.
| Ratio | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| Difference of the Change From Randomization to Day-14 ın the Ratio of the Absolute Counts of CD4+ and CD8+ Markers Between NP-101 and Placebo Arms. | 2.10 ± 0.81 | 2.20 ± 1.11 |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the change in effector immune cells, specifically CD4+ and CD8+ T lymphocytes, from Randomization to Day 7 and Day 14 in participants taking the MED of NP-101 as compared to placebo. We have a total of 36 markers for CD4+ and CD8+. Flow cytometry markers are combinations of the following immune cell types having various immune responses singly or in combination: CD3, CD5, CD8, CD16, CD19, CD45, CCR7, and CXCR3. The flow-cytomerty markers include the immune cell types: CD3, CD4, CD8, CD16, CD19, CD45, CCR7, and CXCR3. These Markers represent the percentages of the combination of these immune cell types or their percentages in the biological sample.
| Percentage | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| CXCR3⁺ CD8⁺ (%) | 1.68 ± 9.12 | 2.40 ± 8.03 |
| CD45⁺ CCR7⁺ CD8⁺ (%) | -0.29 ± 9.76 | -2.31 ± 10.78 |
| CD45 CCR7 CD8⁺ (%) | 0.77 ± 8.06 | 1.53 ± 6.91 |
| CXCR3⁺ CD4⁺ (%) | -0.38 ± 7.40 | -0.07 ± 7.12 |
| CCR7⁺ CXCR3⁺ CD8⁺ (%) | -0.43 ± 6.17 | 0.15 ± 5.69 |
| CD45 CCR7⁺ CD8⁺ (%) | -0.10 ± 10.67 | -3.18 ± 8.86 |
| CCR7⁺ CXCR3⁺ CD4⁺ (%) | 0.05 ± 2.13 | -0.23 ± 1.86 |
| CD8⁺ CD4⁺ (%) | 0.01 ± 0.52 | 0.00 ± 0.99 |
| CD45⁺ CD16⁺ (%) | -0.86 ± 4.81 | -1.34 ± 5.54 |
| CD45⁺ CD3⁺ CD4⁺(%) | -0.42 ± 4.75 | -0.08 ± 3.54 |
| CD45 CCR7⁺ CD4⁺ (%) | 0.58 ± 7.87 | 1.31 ± 7.82 |
| CD45⁺ CD3⁺ CD8⁺ (%) | -0.35 ± 2.66 | -0.46 ± 4.77 |
| CD45⁺ CCR7 CD8⁺ (%) | -0.07 ± 4.86 | 1.71 ± 3.50 |
| CD45⁺ CD3⁺ (%) | -0.50 ± 4.84 | -0.60 ± 5.50 |
| CD45⁺ CD3⁺ CD19⁺ (%) | 1.17 ± 2.83 | 1.57 ± 2.91 |
| CD45⁺ CCR7⁺ CD4⁺ (%) | -0.38 ± 6.34 | 0.78 ± 7.53 |
| CD45 CCR7 CD4⁺ (%) | 0.58 ± 7.87 | 1.31 ± 7.82 |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the rate of disease progression measured by the worsening by the Covid-19 symptoms from 'none' or 'mild' to 'moderate' or 'severe' and remaining at that level for at least two days before alleviation or resolution, or the experience of hospitalization or death due to Covid-19 symptom worsening in participants taking the MED of NP-101 versus placebo
| Participants | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| Proportion of Participants With Symptom Progression | 8 | 24 |
This outcome measure ONLY APPLIES TO the Phase-IIb (efficacy) component of the trial per protocol. Therefore, the six arms of the Phase-IIa (dose-finding phase, three dose levels of NP-101 and placebo investigated) were not part of this data entry. In this objective, we aim to compare the rate of Long- Covid symptoms in participants taking the MED of NP-101 versus placebo. A patient will be classified as having experienced symptoms indicative of Long- Covid if they reported any new or ongoing mild, moderate, or severe Long- Covid symptoms captured on the daily symptom questionnaire, on any of the following days: Day 30 ± 2 days, Day 37 ± 2 days, or Day 45 ± 2 days
| Participants | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|
| Proportion of Paticipants With Long-Covid Symptoms | 12 | 24 |
Collected over From enrollment until the end of Day 45. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase-IIa NP-101 Dose 3g | 0/15 (0%) | 0/15 (0%) | 4/15 (26.7%) |
| Phase-IIa Placebo, Dose 3g | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Phase-IIa NP-101, Dose 4.8g | 0/15 (0%) | 0/15 (0%) | 6/15 (40%) |
| Phase-IIa Placebo, Dose 4.8g | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Phase-IIa NP-101, Dose 6g | 0/15 (0%) | 0/15 (0%) | 12/15 (80%) |
| Phase-IIa Placebo, Dose 6g | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Phase-IIb NP-101, Dose 6g | 0/50 (0%) | 0/50 (0%) | 12/50 (24%) |
| Phase-IIb Placebo, Dose 6g | 0/60 (0%) | 0/60 (0%) | 21/60 (35%) |
| Event | Phase-IIa NP-101 Dose 3g | Phase-IIa Placebo, Dose 3g | Phase-IIa NP-101, Dose 4.8g | Phase-IIa Placebo, Dose 4.8g | Phase-IIa NP-101, Dose 6g | Phase-IIa Placebo, Dose 6g | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g |
|---|---|---|---|---|---|---|---|---|
| DiarrheaGastrointestinal disorders | 1/15 | 2/5 | 3/15 | 0/5 | 2/15 | 3/5 | 8/50 | 12/60 |
| NauseaGastrointestinal disorders | 0/15 | 3/5 | 2/15 | 1/5 | 2/15 | 0/5 | 3/50 | 4/60 |
| Abdominal PainGastrointestinal disorders | 0/15 | 2/5 | 1/15 | 0/5 | 0/15 | 0/5 | 1/50 | 0/60 |
| HeadacheNervous system disorders | 1/15 | 0/5 | 1/15 | 0/5 | 1/15 | 1/5 | 3/50 | 5/60 |
| Alt IncreasedHepatobiliary disorders | 0/15 | 0/5 | 0/15 | 0/5 | 0/15 | 1/5 | 0/50 | 0/60 |
| Ast IncreasedHepatobiliary disorders | 0/15 | 0/5 | 0/15 | 0/5 | 0/15 | 1/5 | 0/50 | 0/60 |
| Bicarbonate Decreased SerumMetabolism and nutrition disorders | 1/15 | 1/5 | 0/15 | 0/5 | 1/15 | 1/5 | 0/50 | 0/60 |
| Blood Bicarbonate LowRenal and urinary disorders | 0/15 | 0/5 | 0/15 | 0/5 | 0/15 | 1/5 | 0/50 | 0/60 |
| Chest painCardiac disorders | 0/15 | 1/5 | 0/15 | 0/5 | 0/15 | 1/5 | 0/50 | 0/60 |
| DiaphoresisSkin and subcutaneous tissue disorders | 0/15 | 0/5 | 0/15 | 1/5 | 0/15 | 0/5 | 0/50 | 0/60 |
The study enrolled a total of 170 participants, of whom 60 were enrolled during the dose-finding component (Phae-IIa)
| Age, Continuous(Year) | Phase-IIa NP-101, Dose 3g | Phase-IIa Placebo, Dose 3g | Phase-IIa NP-101, Dose 4.8g | Phase-IIa Placebo, Dose 4.8g | Phase-IIa NP-101, Dose 6g | Phase-IIa Placebo, Dose 6g | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 41.53 ± 14.03 | 41.05 ± 7.95 | 47.54 ± 14.72 | 45.51 ± 28.22 | 42.53 ± 13.93 | 47.58 ± 19.13 | 46.04 ± 14.14 | 43.84 ± 14.07 | 44.59 ± 14.49 |
| Sex: Female, Male(Participants) | Phase-IIa NP-101, Dose 3g | Phase-IIa Placebo, Dose 3g | Phase-IIa NP-101, Dose 4.8g | Phase-IIa Placebo, Dose 4.8g | Phase-IIa NP-101, Dose 6g | Phase-IIa Placebo, Dose 6g | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 11 | 1 | 8 | 3 | 12 | 4 | 39 | 38 | 116 |
| Male | 4 | 4 | 7 | 2 | 3 | 1 | 11 | 22 | 54 |
| Race (NIH/OMB)(Participants) | Phase-IIa NP-101, Dose 3g | Phase-IIa Placebo, Dose 3g | Phase-IIa NP-101, Dose 4.8g | Phase-IIa Placebo, Dose 4.8g | Phase-IIa NP-101, Dose 6g | Phase-IIa Placebo, Dose 6g | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Asian | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 2 | 1 | 2 | 1 | 4 | 7 | 20 |
| White | 8 | 3 | 7 | 2 | 4 | 1 | 35 | 34 | 94 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 1 | 5 | 2 | 8 | 2 | 9 | 15 | 45 |
| Ethnicity (NIH/OMB)(Participants) | Phase-IIa NP-101, Dose 3g | Phase-IIa Placebo, Dose 3g | Phase-IIa NP-101, Dose 4.8g | Phase-IIa Placebo, Dose 4.8g | Phase-IIa NP-101, Dose 6g | Phase-IIa Placebo, Dose 6g | Phase-IIb NP-101, Dose 6g | Phase-IIb Placebo, Dose 6g | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 10 | 3 | 10 | 4 | 8 | 2 | 42 | 48 | 127 |
| Not Hispanic or Latino | 5 | 2 | 5 | 1 | 7 | 3 | 8 | 12 | 43 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2023 to primary completion in May 2025, 26 months.
Results were first posted in Aug 2026, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nigella sativa oil · Black Seed Oil Extract Supplement
Novatek Pharmaceuticals